Literature DB >> 1450039

Infusional anthracyclines: is slower better? If so, why?

P Workman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1450039

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.

Authors:  A W El-Kareh; T W Secomb
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

2.  Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation.

Authors:  Astrid Gasselhuber; Matthew R Dreher; Ayele Negussie; Bradford J Wood; Frank Rattay; Dieter Haemmerich
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

Review 3.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

4.  BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-Drug Research (CESAR).

Authors:  R-D Hofheinz; C Porta; G Hartung; A Santoro; A-R Hanauske; K Kutz; A Stern; P Barbieri; E Verdi; R Hehlmann; A Hochhaus
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 5.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.

Authors:  A Gabizon; F Martin
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 7.  Schedule-dependent topoisomerase II-inhibiting drugs.

Authors:  S P Joel; M L Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer.

Authors:  H Anderson; P Hopwood; J Prendiville; J A Radford; N Thatcher; L Ashcroft
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

9.  Extracorporeal Removal of Thermosensitive Liposomal Doxorubicin from Systemic Circulation after Tumor Delivery to Reduce Toxicities.

Authors:  Anjan Motamarry; A Marissa Wolfe; Krishna K Ramajayam; Sanket Pattanaik; Thomas Benton; Yuri Peterson; Pegah Faridi; Punit Prakash; Katherine Twombley; Dieter Haemmerich
Journal:  Cancers (Basel)       Date:  2022-03-04       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.